TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06974110: Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors

Sponsor: MOMA Therapeutics · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 132 pts

Competing Trials Overlap

10 Active Trials

Excess Burn Exposure

$1,727,880

Rescue Site Savings

+$1,130,976

Unlock Full NCT06974110 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06974110 Rescue Dossier →